News | August 10, 2023
Suven Life Sciences posts Q1 FY24 consolidated loss at Rs. 24.09 Cr
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Fully equipped labs with 75-member team set-up and made operational in <100 days
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Theramex were searching for a platform to digitise the manual processes across their R&D landscape
Subscribe To Our Newsletter & Stay Updated
